Apcegen Technologies is Pharmaceuticals in India that focus on Provider business. Founded in 2010. They cover business area such as Provider, digital biopharma platform, affordable bio pharmaceutical, inflammation, recombinant therapeutic, disease, arthritis, cancer, patient, affordable biotechnology base healthcare service, GMP compliant fast track development, bioprocesse, biotherapeutic product.
2010
( 14 years old in 2024 )
Provider
-
B901 Daadys Elixir
Near APMC fruit Market Electronic City - II
Bengaluru, Karnataka 560100
India
Private
Providerdigital biopharma platformaffordable bio pharmaceuticalinflammationrecombinant therapeuticdiseasearthritiscancerpatientaffordable biotechnology base healthcare serviceGMP compliant fast track developmentbioprocessebiotherapeutic product
* We use standard office opening hours in near Apcegen Technologies's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Apcegen Technologies is Pharmaceuticals business from India that founded in 2010 (14 years old in 2024), Apcegen Technologies business is focusing on Provider.
Apcegen Technologies headquarter office and corporate office address is located in B901 Daadys Elixir Near APMC fruit Market Electronic City - II Bengaluru, Karnataka 560100 India.
Apcegen Technologies was founded in India.
In 2024, Apcegen Technologies is currently focus on Provider sector.
Above is snippet of Google Trends for "Provider" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Apcegen Technologies, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
